These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16197617)

  • 1. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
    Heath EI; Gaskins M; Pitot HC; Pili R; Tan W; Marschke R; Liu G; Hillman D; Sarkar F; Sheng S; Erlichman C; Ivy P
    Clin Prostate Cancer; 2005 Sep; 4(2):138-41. PubMed ID: 16197617
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.
    Nguyen DM; Chen A; Mixon A; Schrump DS
    J Thorac Cardiovasc Surg; 1999 Nov; 118(5):908-15. PubMed ID: 10534697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials referral resource. Current clinical trials of 17-AG and 17-DMAG.
    Ivy PS; Schoenfeldt M
    Oncology (Williston Park); 2004 May; 18(5):610, 615, 619-20. PubMed ID: 15209189
    [No Abstract]   [Full Text] [Related]  

  • 4. Heat shock protein inhibitor shows antitumor activity.
    Dunn FB
    J Natl Cancer Inst; 2002 Aug; 94(16):1194-5. PubMed ID: 12189221
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
    Ramanathan RK; Trump DL; Eiseman JL; Belani CP; Agarwala SS; Zuhowski EG; Lan J; Potter DM; Ivy SP; Ramalingam S; Brufsky AM; Wong MK; Tutchko S; Egorin MJ
    Clin Cancer Res; 2005 May; 11(9):3385-91. PubMed ID: 15867239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer.
    Neckers L
    Clin Cancer Res; 2002 May; 8(5):962-6. PubMed ID: 12006507
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
    Heath EI; Hillman DW; Vaishampayan U; Sheng S; Sarkar F; Harper F; Gaskins M; Pitot HC; Tan W; Ivy SP; Pili R; Carducci MA; Erlichman C; Liu G
    Clin Cancer Res; 2008 Dec; 14(23):7940-6. PubMed ID: 19047126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of proteasome activity as a therapeutic target in schizophrenia: possible usefulness of 17-allylamino-demethoxygeldanamycin.
    Martinelli V; Emanuele E
    Med Hypotheses; 2006; 67(2):425-6. PubMed ID: 16677776
    [No Abstract]   [Full Text] [Related]  

  • 9. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
    Ochel HJ; Gademann G
    Anticancer Res; 2006; 26(3A):2085-91. PubMed ID: 16827149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.
    Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
    Cancer Res; 2003 Dec; 63(24):8600-5. PubMed ID: 14695170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone.
    Clarke PA; Hostein I; Banerji U; Stefano FD; Maloney A; Walton M; Judson I; Workman P
    Oncogene; 2000 Aug; 19(36):4125-33. PubMed ID: 10962573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp90 inhibitors in the clinic.
    Pacey S; Banerji U; Judson I; Workman P
    Handb Exp Pharmacol; 2006; (172):331-58. PubMed ID: 16610366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
    Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
    Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models.
    Chung YL; Troy H; Banerji U; Jackson LE; Walton MI; Stubbs M; Griffiths JR; Judson IR; Leach MO; Workman P; Ronen SM
    J Natl Cancer Inst; 2003 Nov; 95(21):1624-33. PubMed ID: 14600095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hsp90 as a therapeutic target in prostate cancer.
    Solit DB; Scher HI; Rosen N
    Semin Oncol; 2003 Oct; 30(5):709-16. PubMed ID: 14571418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
    Nielsen TO; Andrews HN; Cheang M; Kucab JE; Hsu FD; Ragaz J; Gilks CB; Makretsov N; Bajdik CD; Brookes C; Neckers LM; Evdokimova V; Huntsman DG; Dunn SE
    Cancer Res; 2004 Jan; 64(1):286-91. PubMed ID: 14729636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-AAG: mechanisms of antitumour activity.
    Konstantinopoulos PA; Papavassiliou AG
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1471-4. PubMed ID: 16307487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
    Enmon R; Yang WH; Ballangrud AM; Solit DB; Heller G; Rosen N; Scher HI; Sgouros G
    Cancer Res; 2003 Dec; 63(23):8393-9. PubMed ID: 14679001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels.
    Braga-Basaria M; Hardy E; Gottfried R; Burman KD; Saji M; Ringel MD
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2982-8. PubMed ID: 15181088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.